Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns a combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma who have received at least two prior systemic therapies
Findings from the DeLLphi-301 study
Evidence for efficacy is based on the results from KEYNOTE-671 study
New indication concerns monotherapy for the maintenance treatment in adult patients with advanced high-grade epithelial ovarian cancer who are in response following completion of first-line platinum-based chemotherapy
Evidence for efficacy is based on the result from the CHECKMATE-76K
New indication concerns monotherapy in first-line treatment of adults with advanced or unresectable hepatocellular carcinoma
Findings from the U31402-A-J101 study
Findings from the HCRN GU 16–257 study
New indication concerns a combination treatment with carboplatin and paclitaxel for adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer
It also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics
Evidence for efficacy is based on the results from the BCHILD study
It is intended for patients who require systemic treatment following platinum-based chemotherapy with or without immunotherapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
